Acura's analgesic Acurox set to miss user fee date
This article was originally published in Scrip
Executive Summary
Acura Pharmaceuticals has received a preliminary communication from the US FDA on the NDA of its abuse-deterring analgesic, Acurox (oxycodone plus niacin), which will result in the drug missing its June 30th PDUFA date.